Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

• Sponsor: Yarmouk University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05106803
• Collaborator: (none)
• Enrollment: 24
• Location: 1
• Actual Duration (Months): 2
• Patients Per Site Per Month: 12

Study Details

Study Description

Brief Summary

The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Condition or Disease	Intervention/Treatment	Phase
Bacterial Infections; Antibiotic Resistant Infection; Surgical Site Infection	Drug: ciprofloxacin

Detailed Description

Background: Surgical site infections are hospital-acquired, vary from one hospital to another, and can cause significant postoperative morbidity, mortality, and prolonged hospital stay.

Aim: The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Methods: Postsurgical wound samples were collected and processed in a microbiology laboratory using standard microbiological techniques. Antibiotic susceptibility tests were performed using 13 antibiotics covering the gram-positive and gram-negative bacteria using the disc diffusion test.

Study Design

• Study Type: Observational
• Actual Enrollment: 24 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan
• Actual Study Start Date: Aug 1, 2019
• Actual Primary Completion Date: Oct 1, 2019
• Actual Study Completion Date: Oct 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Wound infection Patients with surgical site infection as diagnosed by the attending physician	Drug: ciprofloxacin; Antibiotics used in vitro n the study; Other Names: trimethoprim-sulfamethoxazole norfloxacin erythromycin chloramphenicol gentamicin tetracycline vancomycin amoxicillin/clavulanic acid cefepime penicillin ampicillin clindamycin oxacillin

Outcome Measures

Primary Outcome Measures

1. Positive culture [August 2019 to October 2019]

   Positive swab culture from the wound

Secondary Outcome Measures

1. Gram stain and type of Bacteria [August 2019 to October 2019]

   Gram stain and type of Bacteria grown in culture media

2. Antibiotic Susceptibility [August 2019 to October 2019]

   Antibiotic Susceptibility to the isolated organisms

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Post-Surgical Wound Infection

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Yarmouk University	Irbid		Jordan	21163

Sponsors and Collaborators

• Yarmouk University

Investigators

• Principal Investigator: Raed M Ennab, Department of Clinical Sciences, Faculty Of Medicine, Yarmouk University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Raed M Ennab, Assistant Professor, Yarmouk University
• ClinicalTrials.gov Identifier: NCT05106803
• Other Study ID Numbers: Antibiotic profile in Jordan
• First Posted: Nov 4, 2021
• Last Update Posted: Nov 4, 2021
• Last Verified: Oct 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Raed M Ennab, Assistant Professor, Yarmouk University: antimicrobial; hospital; post-surgical infection; surgery
• Additional relevant MeSH terms: Infections; Communicable Diseases; Surgical Wound Infection; Bacterial Infections; Amoxicillin; Vancomycin; Ciprofloxacin; Clindamycin; Gentamicins; Tetracycline; Penicillins; Erythromycin; Ampicillin; Clavulanic Acids; Clavulanic Acid; Cefepime; Trimethoprim, Sulfamethoxazole Drug Combination; Norfloxacin; Oxacillin; Chloramphenicol; Trimethoprim; Sulfamethoxazole

Study Results

No Results Posted as of Nov 4, 2021